ArticleClinics (Sao Paulo, Brazil)2026
A novel inflammatory score predicts hematoma expansion and 90‑day functional outcomes after spontaneous intracerebral hemorrhage.
Article in Clinics (Sao Paulo, Brazil), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIntracerebral Hemorrhage (ICH) entails high morbidity and rapid clinical deterioration; early risk stratification is critical. Although inflammatory biomarkers correlate with Hematoma Expansion (HE) and outcomes, their incremental value over existing models is uncertain.
methodsThe authors retrospectively included consecutive acute ICH admissions to Tongji Hospital (2012‒2024). An inflammatory score (0‒9) was derived from the first post-admission blood draw (on admission or next morning), all within 24 h of admission, using neutrophil-to-lymphocyte ratio, platelet-to-lymphocyte ratio, monocyte-to-lymphocyte ratio, systemic immune-inflammation index (neutrophil × platelet/lymphocyte), lactate dehydrogenase, and high-sensitivity C-reactive protein. HE was defined as > 6 mL or > 33% on 24‒48 h follow-up Computed Tomography (CT). 90-day outcomes were poor function (modified Rankin Scale [mRS] score 4‒6) and mortality. Multivariable models used multiple imputation.
resultsHE analyses included 1047 patients with baseline and 24‒48 h follow-up CT; 298 (28.5%) had HE. Outcome analyses included 953 patients (94-lacked 90-day follow-up); 399 (41.9%) had mRS 4‒6 and 120 (12.6%) died. The score was independently associated with HE (adjusted Odds Ratio 1.18), poor function (1.27), and mortality (1.30). Adding the score increased the area under the receiver operating characteristic curve (AUC) for HE (0.681 to 0.709; ΔAUC = 0.029; p = 0.007), poor function (0.826 to 0.842; ΔAUC = 0.016; p = 0.014), and mortality (0.815 to 0.838; ΔAUC = 0.022; p = 0.036). Sensitivity analyses, including a ≤ 6 h landmark analysis, inverse probability weighting (IPW) for follow-up availability, and complete-case analyses, yielded similar effects.
conclusionAn admission laboratory-based inflammatory score provides independent, incremental prognostic value for HE and 90-day outcomes after ICH. REGISTRATION-URL: http://www.chictr.org.cn. Unique identifier: ChiCTR-ROC-2,000039365.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.